Biotechnology
Compare Stocks
2 / 10Stock Comparison
SEER vs CDNA
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
SEER vs CDNA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $105M | $1.11B |
| Revenue (TTM) | $16M | $413M |
| Net Income (TTM) | $-79M | $-8M |
| Gross Margin | 40.7% | 48.2% |
| Operating Margin | -5.2% | -3.3% |
| Forward P/E | — | 22.8x |
| Total Debt | $26M | $20M |
| Cash & Equiv. | $41M | $65M |
SEER vs CDNA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Seer, Inc. (SEER) | 100 | 3.3 | -96.7% |
| CareDx, Inc (CDNA) | 100 | 29.6 | -70.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SEER vs CDNA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SEER is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.84
- Rev growth -8.1%, EPS growth -3.0%, 3Y rev CAGR 29.7%
- Lower volatility, beta 0.84, Low D/E 7.9%, current ratio 16.53x
CDNA carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 385.1% 10Y total return vs SEER's -96.7%
- 13.8% revenue growth vs SEER's -8.1%
- -2.0% margin vs SEER's -486.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.8% revenue growth vs SEER's -8.1% | |
| Quality / Margins | -2.0% margin vs SEER's -486.0% | |
| Stability / Safety | Beta 0.84 vs CDNA's 1.39 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +45.2% vs SEER's +1.6% | |
| Efficiency (ROA) | -1.9% ROA vs SEER's -25.7%, ROIC -5.7% vs -21.3% |
SEER vs CDNA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SEER vs CDNA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CDNA leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CDNA is the larger business by revenue, generating $413M annually — 25.3x SEER's $16M. Profitability is closely matched — net margins range from -2.0% (CDNA) to -4.9% (SEER). On growth, CDNA holds the edge at +39.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $16M | $413M |
| EBITDAEarnings before interest/tax | -$76M | $2M |
| Net IncomeAfter-tax profit | -$79M | -$8M |
| Free Cash FlowCash after capex | -$46M | $65M |
| Gross MarginGross profit ÷ Revenue | +40.7% | +48.2% |
| Operating MarginEBIT ÷ Revenue | -5.2% | -3.3% |
| Net MarginNet income ÷ Revenue | -4.9% | -2.0% |
| FCF MarginFCF ÷ Revenue | -2.8% | +15.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.5% | +39.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +8.6% | +126.3% |
Valuation Metrics
CDNA leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $105M | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $90M | $1.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.35x | -53.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 22.85x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 7.52x | 2.92x |
| Price / BookPrice ÷ Book value/share | 0.36x | 3.77x |
| Price / FCFMarket cap ÷ FCF | — | 30.66x |
Profitability & Efficiency
CDNA leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
CDNA delivers a -2.6% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-29 for SEER. CDNA carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to SEER's 0.08x. On the Piotroski fundamental quality scale (0–9), CDNA scores 5/9 vs SEER's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -29.2% | -2.6% |
| ROA (TTM)Return on assets | -25.7% | -1.9% |
| ROICReturn on invested capital | -21.3% | -5.7% |
| ROCEReturn on capital employed | -25.9% | -5.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.08x | 0.06x |
| Net DebtTotal debt minus cash | -$15M | -$46M |
| Cash & Equiv.Liquid assets | $41M | $65M |
| Total DebtShort + long-term debt | $26M | $20M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
CDNA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CDNA five years ago would be worth $2,759 today (with dividends reinvested), compared to $494 for SEER. Over the past 12 months, CDNA leads with a +45.2% total return vs SEER's +1.6%. The 3-year compound annual growth rate (CAGR) favors CDNA at 37.7% vs SEER's -19.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +3.3% | +12.0% |
| 1-Year ReturnPast 12 months | +1.6% | +45.2% |
| 3-Year ReturnCumulative with dividends | -47.2% | +161.1% |
| 5-Year ReturnCumulative with dividends | -95.1% | -72.4% |
| 10-Year ReturnCumulative with dividends | -96.7% | +385.1% |
| CAGR (3Y)Annualised 3-year return | -19.2% | +37.7% |
Risk & Volatility
Evenly matched — SEER and CDNA each lead in 1 of 2 comparable metrics.
Risk & Volatility
SEER is the less volatile stock with a 0.84 beta — it tends to amplify market swings less than CDNA's 1.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDNA currently trades 92.3% from its 52-week high vs SEER's 78.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.84x | 1.39x |
| 52-Week HighHighest price in past year | $2.41 | $23.24 |
| 52-Week LowLowest price in past year | $1.65 | $10.96 |
| % of 52W HighCurrent price vs 52-week peak | +78.0% | +92.3% |
| RSI (14)Momentum oscillator 0–100 | 49.8 | 56.4 |
| Avg Volume (50D)Average daily shares traded | 401K | 667K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SEER as "Hold" and CDNA as "Buy".
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | — | $24.00 |
| # AnalystsCovering analysts | 4 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +11.3% | +7.9% |
CDNA leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
SEER vs CDNA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SEER or CDNA a better buy right now?
For growth investors, CareDx, Inc (CDNA) is the stronger pick with 13.
8% revenue growth year-over-year, versus -8. 1% for Seer, Inc. (SEER). Analysts rate CareDx, Inc (CDNA) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SEER or CDNA?
Over the past 5 years, CareDx, Inc (CDNA) delivered a total return of -72.
4%, compared to -95. 1% for Seer, Inc. (SEER). Over 10 years, the gap is even starker: CDNA returned +385. 1% versus SEER's -96. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SEER or CDNA?
By beta (market sensitivity over 5 years), Seer, Inc.
(SEER) is the lower-risk stock at 0. 84β versus CareDx, Inc's 1. 39β — meaning CDNA is approximately 66% more volatile than SEER relative to the S&P 500. On balance sheet safety, CareDx, Inc (CDNA) carries a lower debt/equity ratio of 6% versus 8% for Seer, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SEER or CDNA?
By revenue growth (latest reported year), CareDx, Inc (CDNA) is pulling ahead at 13.
8% versus -8. 1% for Seer, Inc. (SEER). On earnings-per-share growth, the picture is similar: Seer, Inc. grew EPS -3. 0% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, SEER leads at 29. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SEER or CDNA?
CareDx, Inc (CDNA) is the more profitable company, earning -5.
6% net margin versus -620. 9% for Seer, Inc. — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDNA leads at -5. 5% versus -717. 7% for SEER. At the gross margin level — before operating expenses — CDNA leads at 67. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SEER or CDNA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SEER or CDNA better for a retirement portfolio?
For long-horizon retirement investors, Seer, Inc.
(SEER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84)). Both have compounded well over 10 years (SEER: -96. 7%, CDNA: +385. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SEER and CDNA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.